Davison T S, Vagner C, Kaghad M, Ayed A, Caput D, Arrowsmith C H
Ontario Cancer Institute and Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2M9, Canada.
J Biol Chem. 1999 Jun 25;274(26):18709-14. doi: 10.1074/jbc.274.26.18709.
Mutations in the p53 tumor suppressor gene are the most frequent genetic alterations found in human cancers. Recent identification of two human homologues of p53 has raised the prospect of functional interactions between family members via a conserved oligomerization domain. Here we report in vitro and in vivo analysis of homo- and hetero-oligomerization of p53 and its homologues, p63 and p73. The oligomerization domains of p63 and p73 can independently fold into stable homotetramers, as previously observed for p53. However, the oligomerization domain of p53 does not associate with that of either p73 or p63, even when p53 is in 15-fold excess. On the other hand, the oligomerization domains of p63 and p73 are able to weakly associate with one another in vitro. In vivo co-transfection assays of the ability of p53 and its homologues to activate reporter genes showed that a DNA-binding mutant of p53 was not able to act in a dominant negative manner over wild-type p73 or p63 but that a p73 mutant could inhibit the activity of wild-type p63. These data suggest that mutant p53 in cancer cells will not interact with endogenous or exogenous p63 or p73 via their respective oligomerization domains. It also establishes that the multiple isoforms of p63 as well as those of p73 are capable of interacting via their common oligomerization domain.
p53肿瘤抑制基因的突变是人类癌症中最常见的基因改变。最近发现的p53的两个人类同源物增加了家族成员之间通过保守的寡聚化结构域发生功能相互作用的可能性。在此,我们报告了p53及其同源物p63和p73的同源和异源寡聚化的体外和体内分析。正如之前在p53中观察到的那样,p63和p73的寡聚化结构域可以独立折叠成稳定的同源四聚体。然而,即使p53过量15倍,其寡聚化结构域也不与p73或p63的寡聚化结构域结合。另一方面,p63和p73的寡聚化结构域在体外能够彼此弱结合。p53及其同源物激活报告基因能力的体内共转染试验表明,p53的DNA结合突变体不能对野生型p73或p63发挥显性负作用,但p73突变体可以抑制野生型p63的活性。这些数据表明,癌细胞中的突变p53不会通过其各自的寡聚化结构域与内源性或外源性p63或p73相互作用。这也证实了p63以及p73的多种异构体能够通过它们共同的寡聚化结构域相互作用。
Ann N Y Acad Sci. 2000
Cell Death Differ. 1999-12
Mol Cancer Res. 2004-7
Cell Death Discov. 2025-1-25
Genes (Basel). 2024-12-17
Sci Adv. 2023-10-20
Biomedicines. 2022-6-23
Cancers (Basel). 2021-10-26
Cell Death Dis. 2021-7-27
Front Cell Dev Biol. 2021-7-5